Frederic Winssinger Sells 2,000 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Frederic Winssinger sold 2,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $19.21, for a total value of $38,420.00. Following the transaction, the director owned 5,986 shares in the company, valued at $114,991.06. This represents a 25.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

USANA Health Sciences Price Performance

Shares of USNA stock opened at $19.01 on Wednesday. The company has a market cap of $347.43 million, a price-to-earnings ratio of 21.60, a PEG ratio of 0.94 and a beta of 0.61. The stock has a 50 day simple moving average of $25.10 and a 200-day simple moving average of $28.58. USANA Health Sciences, Inc. has a 1-year low of $18.68 and a 1-year high of $41.52.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Thursday, October 9th. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $200.22 million for the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.96%. USANA Health Sciences has set its Q3 2025 guidance at -0.150–0.150 EPS. Analysts anticipate that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

USNA has been the subject of several research analyst reports. Wall Street Zen downgraded shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Weiss Ratings reissued a “sell (d+)” rating on shares of USANA Health Sciences in a report on Wednesday, October 8th. Finally, Zacks Research downgraded USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 21st. Two research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, USANA Health Sciences currently has a consensus rating of “Reduce” and an average target price of $36.00.

Institutional Trading of USANA Health Sciences

A number of hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. lifted its stake in USANA Health Sciences by 339.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company’s stock worth $27,000 after purchasing an additional 771 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of USANA Health Sciences by 382.5% in the second quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after purchasing an additional 1,901 shares during the last quarter. CWM LLC increased its holdings in shares of USANA Health Sciences by 109.7% in the second quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after purchasing an additional 1,445 shares during the last quarter. AlphaQuest LLC lifted its position in USANA Health Sciences by 300.9% during the first quarter. AlphaQuest LLC now owns 3,412 shares of the company’s stock worth $92,000 after buying an additional 2,561 shares in the last quarter. Finally, Quantbot Technologies LP boosted its stake in USANA Health Sciences by 19.5% during the second quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock worth $121,000 after buying an additional 646 shares during the last quarter. Institutional investors and hedge funds own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.